JPRN-UMIN000030570招募中3 期
Single-blind, multicenter clinical study of donepezil hydrochloride for dysuria in patients with Down syndrome - A study of donepezil hydrochloride for dysuria in Down syndrome
Department of Pediatrics, Nagasaki University Hospital0 个研究点目标入组 48 人开始时间: 2018年1月4日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 12years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Any of the following patients will be excluded: 1)those who have already taken any acetylcholinesterase inhibitor with high CNS selectivity, including Aricept 2)those with serious liver or kidney dysfunction 3)those with drug hypersensitivity 4)those who have been in remission on other medical therapy such as Urapidil 5)those who have been on treatment with other therapeutic agent(s) for dysuria 6)those who need to change therapeutic strategy within 8 weeks of the single-blind study 7)those whom principal investigator judged as inappropriate for this study.
研究者
相似试验
招募中
2 期
A study of donepezil hydrochloride for dysuria in Down syndromeDysuria of the people with Down syndromeDown syndrome, DysuriaJPRN-jRCTs071180032Moriuchi Hiroyuki48
进行中（未招募）
不适用
A multicenter, randomized, double-blind study of dacarbazine with or without Genasense in chemotherapy naïve subjects with advanced melanoma and low LDH (The AGENDA Trial)Advanced Melanoma.MedDRA version: 9.1Level: LLTClassification code 10027480Term: Metastatic malignant melanomaEUCTR2007-003340-30-FRGenta Incorporated300
进行中（未招募）
不适用
A multicenter, randomized, double-blind study of dacarbazine with or without Genasense in chemotherapy naïve subjects with advanced melanoma and low LDH (The AGENDA Trial)Advanced melanomaEUCTR2007-003340-30-DEGenta Incorporated300
进行中（未招募）
不适用
A multicenter, randomized, double-blind study of dacarbazine with or without Genasense in chemotherapy naïve subjects with advanced melanoma and low LDH (The AGENDA Trial)Estudio multicéntrico, aleatorizado y doble ciego de dacarbazina con o sin Genasense® en pacientes con melanoma avanzado y niveles bajos de LDH que no han recibido tratamiento previo con quimioterapia (Ensayo AGENDA)Advanced Melanoma.Melanoma AvanzadoMedDRA version: 9.1Level: LLTClassification code 10027480Term: Metastatic malignant melanomaEUCTR2007-003340-30-ESGenta Incorporated300
进行中（未招募）
不适用
A multicenter, randomized, double-blind study of dacarbazine with or without Genasense in chemotherapy naïve subjects with advanced melanoma and low LDH (The AGENDA Trial) - The AGENDA TrialAdvanced Melanoma.MedDRA version: 9.1Level: LLTClassification code 10027480Term: Metastatic malignant melanomaEUCTR2007-003340-30-CZGenta Incorporated300